SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer, but Safety Questioned

The results of a post-hoc exploratory analysis of the phase III ARIEL3 trial were promising, but with some caveats.

Source: CancerNetwork - March 21, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news